Effects of tadalafil on urinary continence recovery after nerve-sparing robot-assisted radical prostatectomy
https://doi.org/10.21518/2079-701X-2014-19-76-79
Abstract
Phosphodiesterase type 5 (PDE5) inhibitors modulate afferent nerve activity, increase nitric oxide activity resulting in the corpus cavernosal smooth muscle relaxation in the penis, prostate, urethra and bladder neck. According the European Urological Association guidelines, PDE5 inhibitors reduce the severity of moderate to severe symptoms of impaired urination in men with and without erectile dysfunction (ED). An overview of recent literature on the use of PDE5 inhibitors showed that they can be used clinically in the treatment of erectile dysfunction as well as in the therapy of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia and in patients with LUTS after radical prostatectomy. The aim of our study was to evaluate the role of tadalafil in restoring continence in patients after bilateral nerve-sparing robotic radical prostatectomy (bilateral NSRRPE).
Keywords
ингибиторы ФДЭ5,
симптомы нижних мочевых путей,
эректильная дисфункция,
билатеральная нервосберегающая роботизированная радикальная про-статэктомия,
тадалафил,
PDE5 inhibitors,
lower urinary tract symptoms,
erectile dysfunction,
bilateral nerve-sparing robotic radical prostatectomy,
tadalafil
About the Authors
AV Govorov
Urology department, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russia’s Ministry of Health
Russian Federation
Russian Federation
DY Pushkar
Urology department, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russia’s Ministry of Health
Russian Federation
Russian Federation
AO Vasilyev
Urology department, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russia’s Ministry of Health
Russian Federation
Russian Federation
DV Priymak
Urology department, Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Russia’s Ministry of Health
Russian Federation
Russian Federation
References
1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol., 2006, Apr, 49 (4): 651-658.
2. Gacci M, Salvi M, Sebastianelli A, Vignozzi L, Corona G, McVary KT. et al. The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction. Res Rep Urol., 2013, 5: 99-111.
3. Lowe G, Costabile RA. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. J Sex Med., 2012, Jan, 9 (1): 265-270.
4. Cantrell M.A., Baye J., Vouri S.M. Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. Pharmacotherapy, 2013, Jun, 33 (6): 639-649. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC. et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol, 2013, 64 (1): 118-140.
5. Gacci M, Ierardi A, Rose AD, Tazzioli S, Scapaticci E, Filippi S. et al. Vardenafil can improve continence recovery after bilateral nerve sparing prostatectomy: results of a randomized, double blind, placebo-controlled pilot study. J Sex Med, 2010, 7 (1): 234-243.
6. Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA. et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol, 2012, 61: 994-1003.
7. Gandaglia G, Suardi N, Gallina A, Capitanio U, Abdollah F, Salonia A. et al. Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy. J Urol., 2012, 187 (2): 569-574.
Review
For citations:
Govorov A, Pushkar D, Vasilyev A, Priymak D. Effects of tadalafil on urinary continence recovery after nerve-sparing robot-assisted radical prostatectomy. Meditsinskiy sovet = Medical Council. 2014;(19):76-79. (In Russ.) https://doi.org/10.21518/2079-701X-2014-19-76-79
Views:
569
Email this article 